内分泌疗法加上HER2向治疗,是HR+/HER2+晚期乳腺癌患者的另一个有利选择
Yuehua Liang1, Xiaoran Liu1, Zehui Yun1
1Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
对于晚期HR+/HER2+乳腺癌,将HER2向疗法与内分泌疗法结合起来是一个可行的一线治疗方法. 这种方法显示了与化疗组合相比较的疗效,并提供了新的治疗途径.
科学领域:
- 在瘤学瘤学.
- 医学研究 医学研究
背景情况:
- 具有激素受体阳性 (HR+) 和人体表皮生长因子受体2-阳性 (HER2+) 状态的高级乳腺癌 (ABC) 提出了独特的挑战.
- HR和HER2路径之间的交叉会导致HR+/HER2+ ABC中对HER2向治疗产生抗性.
研究的目的:
- 评估将HER2向疗法与内分泌疗法 (ET) 结合为HR+/HER2+ ABC的第一线治疗的疗效.
- 探索HR+/HER2+ ABC的新型治疗策略.
主要方法:
- 临床研究的综述,比较HR+/HER2+ ABC的第一线治疗方法.
- 对HER2向治疗与ET与化疗结合的治疗结果的分析.
主要成果:
- 结合治疗与HER2向治疗和ET并没有劣于HER2向治疗加上化疗,用于HR+/HER2+ ABC的第一线治疗.
- 新兴的药物类别,如抗体药物合物和CDK4/6抑制剂,显示出改善预后的前景.
结论:
- 用HER2向治疗和ET进行一线治疗是HR+/HER2+ ABC的推选择.
- 针对参与瘤增殖的信号通路,为HR+/HER2+ ABC提供了新的治疗途径.
更多相关视频
08:29Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Mitogens and the Cell Cycle
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
